CHICAGO — Docetaxel prolonged DFS and OS when added to radiation for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, according to study results ...

Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Bayer AG is conducting an observational study ...

BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...

docetaxel, cisplatin and 5-FU (DCF), which consisted of 70 mg/m 2 docetaxel and 70 mg/m 2 cisplatin on day 1 plus 750 mg/m 2 5-FU on days 1 to 5 every 3 weeks in three courses (n = 202); or ...

In clinical studies, docetaxel monotherapy demonstrated good response rates and an acceptable toxicity profile in both paclitaxel- and platinum-refractory ovarian cancer patients.

Based on the promising activity of docetaxel–CPT-11 in recurrent ovarian cancer, UK and Finnish investigators conducted a randomised feasibility trial in the first-line setting, where 100 ...

Docetaxel is a well established chemotherapy agent in the treatment of primary breast cancer. Docetaxel is also used alone or as part of a combination regimen to treat secondary breast cancer or ...

Docetaxel is a chemotherapy drug that is used to treat several different types of cancer. On the 19th of May 2004, the United States Food and Drugs Administration (US FDA) approved the use of ...

"We found that the use of docetaxel as a radiosensitizer in cisplatin-ineligible patients," when compared to the use of radiation alone, "led to an improvement in disease-free survival ...

We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer. We enrolled 4950 women with axillary ...

Docetaxel had previously been shown to be more effective than doxorubicin for treating patients with advanced breast cancer. Therefore, researchers wanted to test the drug in patients receiving ...

One hundred nineteen of 122 randomly assigned patients had assessable outcomes. The adaptive randomization assigned 73 patients (60%) to gemcitabine-docetaxel and 49 patients (40%) to gemcitabine ...